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Objective. Elimination of autoreactive cells relies
on Fas-dependent activation-induced cell death mecha-
nisms, an important component of peripheral tolerance.
Defects in Fas or its cognate ligand lead to inefficient
activation-induced cell death and are specific causes of
lymphoproliferative and autoimmune diseases. The
present study was undertaken to investigate a novel
1,4-benzodiazepine (Bz-423) that induces apoptosis and
limits autoimmune disease in NZB/NZW mice, to deter-
mine its activity against lupus-like disease associated
with defective Fas expression. We investigated the Fas-
dependence of its cytotoxic actions, its therapeutic po-
tential in mice deficient in Fas, and its therapeutic
mechanism of action.
Methods. Primary lymphocytes isolated from Fas-
deficient MRL/MpJ-Faslpr (MRL-lpr) mice were tested
for sensitivity to Bz-423. Bz-423 was administered to
MRL-lpr mice for short (1-week) or long (14-week)
periods, and its effects on cell survival were determined
along with measures of nephritis, arthritis, antibody
titers, and Th subpopulations. BALB/c mice were simi-
larly treated to determine if Bz-423 alters normal im-
mune functions in vivo.
Results. Administration of Bz-423 to MRL-lpr
mice significantly reduced autoimmune disease includ-
ing glomerulonephritis and arthritis. Treatment was
associated with decreases in CD4 T cells and an
alteration in the Th1/Th2 balance. At the therapeutic
dosage, Bz-423 did not interfere with normal T and B
cell responses in BALB/c mice, suggesting that this
agent is not globally immunosuppressive.
Conclusion. Bz-423 is a novel immunomodulatory
agent that is active against disease even in the context of
defective Fas signaling. It is a leading compound for
further investigation into the development of selective
therapies for lupus.
Systemic lupus erythematosus (SLE) is an auto-
immune disease characterized by a spectrum of antibod-
ies that recognize self antigens (1–3). Autoantibody–
antigen immune complexes deposit in the tissues of the
heart, brain, lungs, and kidney, incite tissue destruction,
and impair organ function by activating complement and
recruiting inflammatory cells (3). The kidney is particu-
larly vulnerable to disease: at least 40% of all SLE
patients have renal involvement, and the renal disease
associated with lupus has a high mortality rate (4,5).
Lymphocytes are primary targets for pharmacologic
therapy used to treat organ-threatening SLE, and effec-
tive immunosuppressive drugs include corticosteroids,
azathioprine, and cyclophosphamide (6–9). Although
the mechanisms by which these agents exert their effects
on SLE are not fully understood, cytotoxicity against B
and T lymphocytes is strongly implicated (10). Advances
have been made in devising effective treatment regi-
mens; however, use of these agents is still accompanied
by serious complications that limit their administration
and overall clinical benefit (11).
Acquisition of agents that more selectively target
lupus-determining lymphoid cells would significantly ad-
vance SLE treatment. In pursuit of this goal, we previ-
ously identified a novel 1,4-benzodiazepine (designated
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Bz-423) with significant cytotoxicity toward B cell lines
in culture (12). Incubation of cells with Bz-423 provokes
a rapid increase in intracellular superoxide (O2
), and
this reactive oxygen species (ROS) is an upstream signal
that initiates an apoptotic process characterized by
cytochrome c release, mitochondrial depolarization, and
caspase activation. Cell fractionation experiments reveal
that the O2
 response results from the interaction of
Bz-423 with a target in mitochondria. The possibility
that Bz-423–induced responses could be tapped for
therapeutic uses (such as cytoreduction) was first tested
in the (NZB  NZW)F1 (NZB/NZW) mouse model of
lupus, in which germinal center (GC) B cells are patho-
logically expanded, behave as neoplastic clones, and
function as a significant determinant of autoimmune
disease (13–16). Administration of Bz-423 limited GC
hyperplasia and the development of glomerulonephritis
in these mice (12).
We have now extended our studies on this com-
pound and shown that Bz-423 preserves renal function
and reduces nephritis when administered to MRL/MpJ-
Faslpr (MRL-lpr) mice, a strain in which peripheral
autoreactive T cells drive a lupus-like disease process
(17–20). Treatment is associated with a change in the
Th1/Th2 cell balance and small decreases in specific T
cell subsets. In addition, we found that treating normal
immune mice with Bz-423 did not affect lymphocyte
activation, T cell–dependent delayed-type hypersensitiv-
ity (DTH), or T cell–dependent antibody production.
We derived a mechanistic hypothesis to explain the
activity of Bz-423 in autoimmune mice and the lack of an
immunosuppressive effect in normal animals.
MATERIALS AND METHODS
Animals and Bz-423 treatment. These studies were
approved by the University of Michigan Committee on the Use
and Care of Animals. Female MRL-lpr mice were purchased
from Jackson Laboratories (Bar Harbor, ME). Female
BALB/c mice were purchased from Charles River Laborato-
ries (Wilmington, MA). Bz-423 was synthesized as previously
described (21) and dissolved in DMSO as the vehicle. For the
longitudinal study, control mice received vehicle (50 l
DMSO; n  11), and treatment mice received Bz-423 (60
mg/kg; n  10) injected intraperitoneally. Peripheral blood was
collected from the tail vein for complete blood cell counts and
preparation of serum. Mice were killed by CO2 asphyxiation.
Kidneys were bisected and fragments fixed in 10% buffered
formalin or snap-frozen in OCT. Spleen fragments were
processed in buffered formalin, frozen in OCT, or used to
prepare single cell suspensions.
Cell culture. Single cell suspensions from freshly iso-
lated spleens of untreated animals were prepared by disaggre-
gating the tissue with forceps and lysing red blood cells. Cells
(106/ml) were maintained on ice in RPMI (Mediatech, Hern-
don, VA) supplemented with penicillin (100 units/ml), strep-
tomycin (100 g/ml), L-glutamine (290 g/ml),
2-mercaptoethanol (50 g/ml), and heat-inactivated fetal bo-
vine serum (FBS) (2%; Summit Biotechnology, Santa Ana,
CA). Viability experiments were conducted in this same media
at 37°C in a 5% CO2 atmosphere. Bz-423 and other drugs were
dissolved in DMSO that was present at a final concentration of
0.5% (volume/volume). After treatment, cells were incubated
for 15 minutes with propidium iodide (PI) (1 g/ml), and
viability assessed by flow cytometry based on PI exclusion (22).
Data were collected and analyzed using a FACSCalibur (BD
Biosciences, San Diego, CA). For each sample, 10,000 events
were recorded and the data were analyzed excluding aggre-
gates.
Fluorescence analysis of lymphocyte populations. Sur-
face markers were detected by incubating (20 minutes, 4°C)
single cell suspensions with fluorescein isothiocyanate–
conjugated (2.5 g/106 cells) or phycoerythrin-conjugated (1
g/106 cells) rat anti-mouse antibodies (anti-Thy 1.2, clone
53-2.1; anti-CD4, clone H129.19; anti-CD8a, clone 53-6.7;
anti-B220, clone RA3-6B2; anti-CD69, clone H1-2F3)
(PharMingen, San Diego, CA). Viability was simultaneously
measured with PI. Data were collected and analyzed by flow
cytometry.
Antibody titers, blood urea nitrogen, and proteinuria.
Autoantibody (anti-DNA, antihistone, anti-Ro, anti-La) and
total immunoglobulin (IgG, IgM) titers were determined by
enzyme-linked immunosorbent assay (ELISA) as previously
described (23). Serum blood urea nitrogen was measured at
the clinical pathology laboratory, University of Michigan Hos-
pital. Proteinuria was measured using ChemStrip 6 (Boehr-
inger Mannheim, Indianapolis, IN).
Histologic analysis. Formalin-fixed sections were
stained with hematoxylin and eosin (H&E), periodic acid–
Schiff, or Masson’s trichrome as previously described (24).
Kidney sections were examined by a renal pathologist (who
was blinded to the treatment group) and were scored for
glomerulonephritis on a 0–4 scale based on the degree of
cellularity, scarring, and crescent formation. Glomerular anti-
body deposition was assessed by immunofluorescence staining
of frozen sections of kidneys (25). Formalin-fixed limbs were
processed, sectioned, and stained with H&E. The intercarpal,
metacarpophalangeal, and interphalangeal joints were exam-
ined. Under blinded conditions, synovitis was graded on a scale
of 0–3 based on the degree of synovial proliferation, trans-
formation of the synoviocytes, and pannus development. Ero-
sions (both cartilage and bone) were noted as being present or
absent.
Cytokine enzyme-linked immunospot assays. Assays
were conducted in 96-well Multiscreen-IP plates (Millipore,
Bedford, MA), and pairs of cytokines were assayed together:
interleukin-2 (IL-2) and IL-4, IL-10 and interferon- (IFN).
Plates were coated (18 hours, 4°C) with capture antibodies (5
g/ml in 100 mM carbonate, pH 8.2) specific for each cytokine
(rat anti-mouse IL-2 [antibody 702], IL-4 [antibody 404], IL-10
[antibody 417], and IFN [antibody 786]) (R&D Systems,
Minneapolis, MN). Single cell suspensions of splenocytes from
treatment and control MRL-lpr mice were prepared as de-
scribed above. Cells (103–106/well) were added to the plates
and cultured (18 hours, 37°C, 5% CO2) in Dulbecco’s modified
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Eagle’s medium (Mediatech) containing FBS (10%), penicillin
(100 units/ml), streptomycin (10 g/ml), L-glutamine (2 mM),
and concanavalin A (2 g/ml) (all from Sigma, St. Louis, MO).
After washing, the wells were incubated with primary antibod-
ies specific for each cytokine: 2 g/ml of goat anti-mouse IL-2
(AB-402-NA; R&D Systems), rat anti-mouse IL-4 (biotinyl-
ated) (18042D; PharMingen), or hamster anti-mouse IFN
(1222-00; R&D Systems), or 188 ng/ml of goat anti-mouse
IL-10 (biotinylated) (BAF417; R&D Systems). After further
washing, appropriate species-specific enzyme-conjugated sec-
ondary antibodies and substrates were used for detection.
In vivo T cell activation. BALB/c mice (11 weeks old)
were administered 2 doses of Bz-423 (60 mg/kg; n  5) or
vehicle (n  5) at 24-hour intervals. Anti-CD3 (clone F500;
PharMingen) was given intraperitoneally (25 g in 100 l of
phosphate buffered saline [PBS]) 2 hours after the last injec-
tion of Bz-423. Mice were killed 24 hours after treatment, and
the spleens were removed. Single cell suspensions were pre-
pared and analyzed by flow cytometry for surface marker
expression.
DTH testing. BALB/c mice (10 weeks old) were in-
jected every other day with either Bz-423 (60 mg/kg; n  10) or
vehicle (n  10) for 1 week. The dorsal flanks were injected
subcutaneously with 2,4,6-trinitrobenzenesulfonic acid (TNBS)
(10 mM in PBS, pH 7.4; Sigma). A subset of mice from both
the vehicle group (n  5) and the Bz-423 group (n  5) did not
receive this initial TNBS (nonsensitized). Administration of
Bz-423 or vehicle continued, and the mice were challenged
with TNBS in the left hind footpad 7 days after the first
immunization with TNBS. The nonsensitized mice also re-
ceived this challenge to measure inflammation resulting from
the injection process. Footpad thickness was measured 4 hours
and 24 hours later, using micrometer calipers. Induration was
calculated by subtracting the right hind footpad thickness from
that of the left.
T cell–dependent antibody response. BALB/c mice (10
weeks old) were injected with Bz-423 (60 mg/kg; n  4) or
vehicle (n  4) every other day for 1 week. All mice were
immunized intraperitoneally with keyhole limpet hemocyanin
(KLH) (50 g; Pierce, Rockford, IL) in Freund’s complete
adjuvant (total volume 0.5 ml; Sigma). Administration of
Bz-423 (or vehicle) was continued, and 28 days after the first
immunization, mice were boosted with KLH in Freund’s
incomplete adjuvant (Sigma). Serum samples were obtained
on day 49 (post–first immunization) and analyzed by ELISA
for anti-KLH titers. For the ELISA, microtiter plates were
coated with KLH (0.1 mg/ml in PBS) and anti-KLH concen-
tration was quantified by comparison with a standard curve
generated with rabbit anti-KLH (ICN Biomedicals, Costa
Mesa, CA).
Statistical analysis. Statistical significance was as-
sessed using the Mann-Whitney U test (1-tailed) unless other-
wise noted. P values are 1-tailed, and data are presented as the
mean  SEM.
RESULTS
Fas-independent killing of B and T cells by
Bz-423. The lpr mutation blocks death receptor–initiated
apoptosis and also prevents the apoptotic response to
certain small molecules (e.g., doxorubicin) (26). To
determine if Fas is necessary for the activity of Bz-423,
we examined the cytotoxic activity of Bz-423 against
spleen cells from autoimmune MRL-lpr mice, a murine
model of SLE in which defective Fas signaling, particu-
larly within the T cell compartment, plays a dominant
role in mediating disease (19,20). Freshly isolated
splenocytes cultured with Bz-423 were rapidly killed by
Bz-423 in a concentration- and time-dependent manner
(data not shown). This effect was specific to Bz-423:
other benzodiazepines, i.e., diazepam and clonazepam,
and controls, i.e., 1-napthol and 1-(2-chlorophenyl-N-
methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide,
were not cytotoxic.
To determine if cell lineage is associated with
differing sensitivity to Bz-423, mixed splenocytes were
treated under conditions that afford 80% overall cell
death (for Bz-423, 10 M, 12 hours). The relative
proportion of B, T, and CD4 T and CD8 T cells
remaining viable after culture remained nearly identical
to their proportions in untreated controls (data not
shown). These results indicate that, although Bz-423 is
an effective cytotoxic agent against cells with defective
Fas signaling, there is no in vitro selectivity between
MRL-lpr splenic lymphocyte lineages and subsets.
Selective reduction of splenic T cells with brief
administration of Bz-423 to MRL-lpr mice. Previous
experiments have shown that administering Bz-423 to
NZB/NZW mice for 1 week killed splenic B cells, and
extended dosing reduced GC B cells and improved
autoimmune disease (12). Based on these data and the
results showing activity against MRL-lpr cells in vitro, we
investigated whether Bz-423 is cytoreductive in MRL-lpr
mice. MRL-lpr mice received either Bz-423 (60 mg/kg)
or vehicle control daily for 1 week. Splenocytes from
mice treated with Bz-423 had lower viability (mean 
SEM 82  1% in controls versus 75  3% in Bz-423–
treated mice; P  0.008) and significantly fewer T cells
(Thy1.2), CD4 T cells, and double-negative T cells
(Thy1.2, B220, CD4, CD8) (Table 1). The selec-
tive reduction of MRL-lpr T cells by Bz-423 indicates
that its effects in vivo are modulated by factors that are
not represented by the in vitro model of lymphotoxicity,
and differences between NZB/NZW and MRL-lpr mice
confer differential susceptibility to this benzodiazepine.
Amelioration of disease in Bz-423–treated MRL-
lpr mice. Since CD4 T cells are required for autoanti-
body production and fulminant nephritis and arthritis in
MRL-lpr mice (27–29), extended dosing with Bz-423
might improve disease in this strain. To test this hypothe-
sis, we designed an experiment in which mice were
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injected with either Bz-423 or vehicle control every other
day beginning at 8 weeks of age as described in Materials
and Methods. The study continued until mice were 22
weeks old (14 weeks of treatment), when mortality from
renal failure typically is near 50% (30). Each animal was
monitored weekly for renal function (proteinuria) and
analyzed at the end of the study to determine effects on
autoimmune nephritis, arthritis, lymphoproliferative dis-
ease, and autoantibody titers.
Mice treated with Bz-423 developed significantly
less proteinuria (Figure 1) and had lower serum blood
urea nitrogen levels measured after 14 weeks of treat-
ment (mean  SEM 27  5 mg/dl, versus 44  14 mg/dl
in controls; P  0.0024). The reduction in azotemia was
associated with less histopathologic evidence of nephritis
at the end of the study (Figures 2 and 3). Treatment was
also associated with preservation of normal glomerular
architecture: mice administered Bz-423 had less cellular
infiltration, fibrosis, and crescent formation compared
with controls (average histopathologic score after treat-
ment 2 in Bz-423–treated mice versus 4 in control
mice; P  0.02). Similarly, complement deposition in the
glomeruli was also decreased (mean score 1–2 and
3–4 in Bz-423–treated and control mice, respectively;
P  0.007). By the end of the study, 40% of controls and
none of the Bz-423–treated mice had died with evidence
of significant renal disease (Figure 3). Histopathologic
examination of joints revealed marked synovitis, synovial
cell proliferation, pannus formation, and erosion of
articular cartilage and subchondral bone in control
animals. In contrast, synovitis was significantly reduced
in mice that received Bz-423, and fewer treated mice had
Figure 1. Protection of renal function with Bz-423 treatment. MRL-
lpr mice were treated with Bz-423 (60 mg/kg every other day) (solid
line) or vehicle (dashed line) for 14 weeks. Urine was tested weekly
and disease defined as an elevated urine protein level (2; 100
mg/dl) observed in 2 consecutive weeks. P value was determined by
Kaplan-Meier analysis.
Figure 2. Reduction of kidney and joint disease with Bz-423 treat-
ment. MRL-lpr mice were treated for 14 weeks with Bz-423 or vehicle
(control) as described in Figure 1. Glomeruli from control mice (A and
C) and Bz-423–treated mice (B and D) were stained with hematoxylin
and eosin (H&E) (A and B) or with immunofluorescence to detect C3
deposition (C and D). Joints from the hind paws of control mice (E)
and Bz-423–treated mice (F) were stained with H&E. Arrows indicate
synovial thickening; arrowhead indicates bony erosion. (Magnification
400 in A–D and F; 200 in E.)







T cells 23.5  1.9 18.1  1.0 0.016
B cells 19.3  1.5 17.6  0.6 0.15
Double-negative T cells 7.8  0.7 5.3  1.1 0.005
CD4 T cells 10.9  1.0 8.5  0.3 0.031
CD8 T cells 5.8  0.3 6.7  0.4 0.06
* Ten-week old MRL-lpr mice were treated daily with Bz-423 (60
mg/kg; n  10) or vehicle control (n  10) for 7 days. Cells were
quantified based on the total number of splenocytes recovered and
flow cytometric determination of surface markers. T cells were defined
by the expression of Thy1.2, and subsets were differentiated based on
coexpression of CD4 or CD8. Double-negative T cells were identified
by the presence of Thy1.2 and B220, and B cells by B220 without
Thy1.2. P values were determined by Student’s t-test. Values are the
mean  SEM total cells  106.
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evidence of articular erosion or pannus formation (Ta-
ble 2 and Figure 2).
Reductions in spleen weight or lymphoprolifera-
tive disease (scored histopathologically) were not ob-
served (data not shown), providing evidence against a
lymphoablative effect. Moreover, at the end of the study,
differences in blood counts (hematocrit, platelets, total
white blood cells) were not detected between treatment
and control animals (data not shown), which suggests
that at the dosage used, Bz-423 does not interfere with
hematopoiesis. In contrast, serum levels of autoantibod-
ies (anti-DNA, antihistone, and anti-La) were slightly
reduced in Bz-423–treated animals (Table 3), whereas
total IgG and total IgM were not altered (mean  SEM
IgG level 26  3.9 mg/ml in control mice versus 23  2.5
mg/ml in treated mice [P  0.33]; IgM level 0.33  0.06
mg/ml in control mice versus 0.34  0.1 mg/ml in treated
mice [P  0.23]). Treatment of MRL-lpr mice with
Bz-423 for 14 weeks reduced splenic CD4 T cells,
while changes in CD8 T cells, double-negative T cells,
or B cells were not observed (Table 4). Analysis of T cell
subsets by enzyme-linked immunospot assay demon-
strated a particular reduction in Th2 cells after dosing
with Bz-423 (fewer IL-4– and IL-10–producing cells)
with an increase in Th1 (IFN)–secreting cells, although
the numbers of cells secreting IL-2 were similar
(Table 5).
Bz-423 does not interfere with normal immune
function. Our findings with both NZB/NZW and MRL-
lpr mice demonstrate that Bz-423 has a therapeutic
effect against murine lupus. To investigate the general
immunomodulatory properties of Bz-423, we designed a
series of experiments to determine if the therapeutic
dosage interferes with normal immune responses. Since
normal immune functions are perturbed in the NZB/
NZW and MRL-lpr strains (31,32), BALB/c mice were
used in these studies. In the first group of experiments,
BALB/c mice were given Bz-423 (60 mg/kg) or vehicle
Figure 3. Decrease in glomerulonephritis with Bz-423 treatment.
MRL-lpr mice were treated for 14 weeks with Bz-423 or vehicle
(control) as described in Figure 1. At the termination of the treatment
period, glomerulonephritis was scored using criteria described in
Materials and Methods. Open circles represent mice that died during
the treatment period. Histologic data were available for only 1 of the
3 Bz-423–treated mice that died during the study; however, all 3 mice
had proteinuria measurements of 2 prior to death, indicative of
minimal glomerular disease. These animals died as a result of intra-
peritoneal adhesions causing bowel obstruction; the adhesions were
caused by the injections.






Mean synovitis score 2–3‡ 1 0.001
No. of mice with 2 synovitis 7 0 0.01
No. of mice with erosions 4 2 0.3
No. of mice with pannus formation 4 1 0.13
* Hind paws were evaluated histopathologically and scored for syno-
vitis on a 0–3 scale (n  7 in each group). Erosions (bony and
cartilaginous) and pannus formation were noted as present or absent.
† Determined by Mann-Whitney U test for synovitis score and by
cross-tabulation with chi-square analysis for number of mice with 2
synovitis, erosions, and pannus formation.
‡ Scores of 2 in 4 mice and 3 in 3 mice.






Anti-ssDNA, units/ml 887  124 508  73 0.02
Anti-dsDNA, units/ml 650  172 247  38 0.08
Antihistone, OD405 1.4  0.2 0.6  0.2 0.006
Anti-La, units/ml 529  174 226  61 0.03
Anti-Ro, units/ml 456  124 304  97 0.16
* Values are the mean  SEM. ELISA  enzyme-linked immunosor-
bent assay; anti-ssDNA  anti–single-stranded DNA; anti-dsDNA 
anti–double-stranded DNA; OD405  optical density at 405 nm.







T cells 76  2 73  4 0.24
B cells 7  1 7  2 0.44
Double-negative T cells 32  4 31  4 0.50
CD4 T cells 38  3 33  2 0.05
CD8 T cells 16  1 17  2 0.30
* Percentage representation of each population was determined by
surface marker staining as described in Table 1. Values are the mean 
SEM.
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for 7 days and examined for evidence of lymphotoxicity.
After treatment, the total number of splenic lympho-
cytes (Bz-423–treated mice mean  SEM 47  6  106
cells, control mice 49  3  106 cells; P  0.37), T cells
(Bz-423–treated mice 20  3  106 cells, control mice
21  1  106 cells; P  0.42), and B cells (Bz-423–
treated 27  4  106 cells, control mice 28  2  106
cells; P  0.35) in BALB/c mice were not altered by
Bz-423. In comparison, a single therapeutic dose of
cyclophosphamide (100 mg/kg) (33) reduced lymphocyte
numbers by 30%, which was primarily accounted for by
a reduction in B cells (data not shown). The absence of
a cytoreductive effect of Bz-423 in BALB/c mice indi-
cates that at the dose tested, Bz-423 may have selectivity
for lymphocytes and/or processes associated with auto-
immunity.
We next sought to address the possibility that the
therapeutic activity of Bz-423 in MRL-lpr mice princi-
pally involves modulation of a functional immune re-
sponse rather than direct cytotoxic action against auto-
immune cells. Such an alternative might account for the
apparent discrepancy between the relatively small over-
all decrease in lymphocytes and the much larger effects
of 14 weeks of treatment on disease end points and the
Th1/Th2 balance. Experiments were designed to specif-
ically determine if Bz-423 affects 1) lymphocyte activa-
tion, 2) T cell–dependent DTH responses, and 3) T
cell–dependent antibody production.
To study activation, BALB/c mice were chal-
lenged with a single dose of anti-CD3 (25 g) to
polyclonally stimulate T cells (34). Mice received 2 doses
of Bz-423 (60 mg/kg) or vehicle 24 hours and 2 hours
prior to the injection of anti-CD3. Mice were killed 24
hours after anti-CD3 administration, and splenic T cell
populations were enumerated for CD69 expression (an
early activation marker) (35) by flow cytometry. Stimu-
lation with anti-CD3 resulted in a 30-fold increase in the
percentage of activated T cells (CD69, Thy1.2) (un-
stimulated 0.3  0.1%, anti-CD3–stimulated 9  1%
[mean  SEM]). This response was not diminished by
treatment with Bz-423 (CD69, Thy1.2 12  1%).
Indeed, the data even suggest a small increase in the
fraction of CD69 T cells in Bz-423–treated mice. On
this basis, we conclude that Bz-423 does not prevent T
cell activation in vivo.
A DTH assay in which mice were sensitized to
TNBS (36,37) was used to assess T cell–dependent
cellular immune function. In the treatment group, mice
received Bz-423 (60 mg/kg every other day) for 1 week
and then were injected once with TNBS, after which the
dosing of Bz-423 was continued. After an additional 7
days, the mice were challenged with TNBS in the hind
footpad and the DTH response was judged by measuring
induration of the footpad 24 hours later. As seen in
Table 6, the responses in mice receiving Bz-423 were
statistically indistinguishable from those in control mice.
Lastly, BALB/c mice were challenged with KLH
to assess T cell–dependent antibody production (38,39).
Bz-423 was administered to BALB/c mice for 1 week (60
mg/kg every other day) prior to immunization with
KLH, and dosing with Bz-423 was continued throughout
the study. The animals were boosted with KLH 28 days
after the initial challenge, and antibody levels were
quantified 21 days later. Anti-KLH and total IgG titers
were statistically indistinguishable in Bz-423–treated and
control mice (Table 6), implying that exposure to Bz-423
Table 5. Effect of Bz-423 on cytokine-producing splenocytes mea-






No. of cells (105)
secreting IL-2
99  18 79  19 0.21
No. of cells (105)
secreting IL-4
102  27 15  12 0.001
No. of cells (105)
secreting IL-10
14  5 1.1  0.3 0.001
No. of cells (105)
secreting IFN
203  29 422  36 0.001
* Values are the mean  SEM. IL-2  interleukin-2; IFN 
interferon-.








Immunized 4.8  1.0 22  8
Nonimmunized 2.9  0.2 –
Bz-423–treated
Immunized 4.0  1.5 18  1
Nonimmunized 2.5  0.9 –
* BALB/c mice were treated with Bz-423 (60 mg/kg every other day) or
vehicle for 1 week prior to immunization, and dosing was continued
throughout the study. For the delayed-type hypersensitivity (DTH)
experiment, mice were immunized with 2,4,6-trinitrobenzenesulfonic
acid (TNBS) or left untreated. After 7 days, all mice were challenged
with TNBS in the left hind footpad, and footpad thickness was
measured after 24 hours. Results are reported as left minus right
footpad thickness. For the keyhole limpet hemocyanin (KLH) exper-
iment, mice were immunized with KLH and boosted 28 days later.
Antibody production in response to KLH was measured 21 days after
the boost. Values are the mean  SEM (n  5 for TNBS studies; n 
4 for KLH studies). Values determined in Bz-423–treated mice were
not statistically significantly different from those in control mice.
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does not suppress normal lymphoid responses required
for antibody production.
Collectively, these results indicate that Bz-423
does not block normal immune responses or deplete
lymphocytes in BALB/c mice. Furthermore, they pro-
vide evidence against the possibility that Bz-423 controls
lupus by nonspecifically dampening overall immune
system function or by interfering with critical elements
of the normal immune response.
DISCUSSION
In previous work (12), we characterized the pro-
apoptotic properties of Bz-423 and its efficacy against
nephritis in NZB/NZW mice, a murine model of SLE in
which B cells play a central role in the development and
pathogenesis of disease. The present study tested the
effectiveness of Bz-423 in MRL-lpr mice, a second
model of SLE, in which disease is primarily controlled by
T cells that are defective in Fas-mediated activation-
induced cell death (AICD) (17–20). Administering Bz-
423 to MRL-lpr mice reduces autoimmune nephritis and
improves survival. The reduction in nephritis, deter-
mined histopathologically at the end of the study, was, as
expected, accompanied by improved renal function (less
proteinuria) throughout the course of treatment. In
addition, treated mice had a blunted humoral auto-
immune response, with lower serum concentrations of
anti–single-stranded DNA, anti–double-stranded DNA,
and histone antibodies. These specific immunoglobulin
changes, however, occurred in the context of unchanged
total IgG and IgM levels and normal blood cell count
indices. Thus, Bz-423 diminishes the immune response
to autoantigens without altering total immunoglobulin
levels and without suppressing bone marrow hematopoi-
esis.
In contrast to nephritis, arthritis in MRL-lpr mice
is independent of circulating antibodies (e.g., rheuma-
toid factor) and is directly mediated by activated CD4
T cells (40). Hence, the effect of Bz-423 on preventing
arthritic changes suggests a mechanism involving CD4
T cells. Indeed, our observations that 8-week-old ani-
mals dosed for 1 week have reduced CD4 and double-
negative T cell subsets and that 22-week-old mice
treated for 14 weeks have fewer CD4 T cells than
controls supports the notion of a T cell–specific effect.
In experiments with NZB/NZW mice, GC B cells
displayed the greatest sensitivity to Bz-423 (12). Paral-
lels between NZB/NZW GC B cells and MRL-lpr T cells
suggest a possible mechanism to explain the observed
cell-type selectivity in the 2 strains. In MRL-lpr mice,
the lpr mutation prevents proper Fas signaling (19,20).
Consequently, AICD of T cells is defective, which
results in an expanded population of activated CD4 T
cells, some of which mediate autoimmune disease. In
the NZB/NZW model, the B cell population has an
activated phenotype and persists abnormally due to a
failure of B cell AICD, normally triggered by B cell
receptor (BCR) crosslinking (41–44). Of note, although
Fas and Fas ligand are intact in the NZB/NZW strain,
defective AICD and the development of autoreactive B
cells has been linked to resistance against Fas-mediated
apoptosis (45).
Thus, persistent activation is a common factor in
cells targeted by Bz-423, suggesting that activation,
particularly in the absence of functional AICD mecha-
nisms, may enhance sensitivity to Bz-423 killing. In
support of this hypothesis, preliminary experiments
show that BCR stimulation and secondary activation of
T cells significantly increase the apoptotic responsive-
ness to Bz-423 (Bednarski JJ, et al: unpublished obser-
vations). In addition, the molecular mechanism of Bz-
423 killing involves O2
 generated by mitochondria. In
this regard, it is also worth noting that activated auto-
immune T lymphocytes have reduced levels of antioxi-
dants to detoxify ROS, including O2
 (46,47). Hence, a
molecular signal generated by Bz-423 intersects with a
point of inherent vulnerability in activated autoimmune
T cells, which may contribute to the selectivity observed
in vivo.
At the therapeutic dose, administration of Bz-423
to normal immune mice did not reduce either T or B
cells and did not significantly interfere with experimen-
tally induced humoral- or cell-mediated immune re-
sponses. Hence, Bz-423 is not a broad-acting immuno-
suppressive agent like prednisone or cyclophosphamide,
which also effectively treat lupus (48). Mechanistically,
this information is consistent with the model proposed
above, in which activation sensitizes cells to Bz-423. In
the normal immune state, AICD mechanisms are intact,
limiting the survival and number of activated T cells
(49). The cytotoxic action of Bz-423, if concentrated
on activated immune cells as proposed above, assumes
importance only when normal mechanisms of AICD
fail, such as in autoimmune disease. Hence, the pro-
posed activity of Bz-423 is redundant with normal phys-
iologic mechanisms and therefore, unlikely to signifi-
cantly modulate normal immune behavior. It remains a
possibility, however, that selectivity is dose dependent
and that higher doses of Bz-423 would be broadly
lymphotoxic.
Although disease pathogenesis in MRL-lpr mice
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requires CD4 T cells, a clear understanding of the
individual roles of Th1 and Th2 subsets in this disease
has not emerged (50). IL-4, IL-10, and IFN play
important, but complex, roles in the pathogenesis of
murine and human lupus (51). Analysis of the Th1/Th2
cytokine response in mice treated with Bz-423 reveals a
significant change relative to controls: Bz-423 caused a
marked decrease in the Th2 cell response (IL-4– and
IL-10–secreting spleen cells) and an increase in Th1
(IFN)–producing cells. Disease in MRL-lpr mice has
been associated with increased Th1 cells (IFN), as well
as increased Th2 cells (IL-4 and IL-10), relative to
normal immune mice (52,53). In experimental lupus
induced in BALB/c mice by idiotypic manipulation and
in the natural disease course in NZB/NZW mice, in-
creased levels of IL-4 and IL-10 have been detected
(54,55). Treatment with IL-4 antagonists decreases anti-
DNA titers and reduces renal disease (56). Backcrossing
MRL-lpr mice with IL-4 knockout mice produces a
phenotype with less renal disease and diminished adeno-
pathy (57).
Experimental treatment of lupus mice with a new
benzoquinone-containing natural product reduces auto-
antibodies and nephritis, and also affects the Th1/Th2
balance by inhibiting the Th2 response (58). Because
Th2 cells support B cell development and the humoral
arm of the autoimmune response, the Th2 reduction
may underlie the effects on autoantibody production
and nephritis in Bz-423–treated mice. This important
connection could account for the observed reduction in
autoantibody titers, which occurred in the absence of a
cytoreductive effect on B cells.
It is possible that the increase in IFN-secreting
cells associated with Bz-423 treatment also contributes
to the observed therapeutic responses. Depending on
the specific model and stage of disease, IFN has been
associated with both autoimmune disease promotion
and disease protection (59,60). In accordance with our
results, IFN has a particularly important role in limiting
joint disease in murine arthritis induced by collagen
injection (61,62). Conversely, the phenotype of MRL-lpr
mice in which IFN is knocked out is improved with
respect to glomerulonephritis (63,64), providing evi-
dence that IFN in fact promotes disease. These find-
ings conflict with the results of antibody-blocking exper-
iments that fail to show a significant contribution of
IFN to MRL disease (65). These differences may be
explained by an age-dependence on the effects of IFN,
which has been observed in the antiidiotype model of
lupus as well as in MRL-lpr mice (55,60). Given this
complexity, additional experiments are necessary to
elucidate whether the Th1/Th2 response to Bz-423 is
significant with regard to its therapeutic effects.
In conclusion, our data indicate that Bz-423 is a
leading compound for studies aimed at development of
more selective cytotoxic molecules with properties use-
ful for treating SLE and possibly other related disorders.
Investigations in progress are directed at defining the
molecular target of Bz-423 as a basis to advance drug
discovery and at further testing of the proposed model
as an explanation for the observed selectivity in vivo.
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